Cyclosporine pharmacokinetics in anti-HCV + patients

Clinical Transplantation

Volumn 18, Issue 6, 2004, Pages 654-660

  Wolffenbüttel, Luciano ^a,b,c   Poli, Débora D ^a,b   Manfro, Roberto C ^a,b   Gonçalves, Luiz Felipe S ^a,b  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c NONE   (Brazil)

Author keywords

Cyclosporine; Hepatitis C; Kidney transplantation; Pharmacokinetics

Indexed keywords

AZATHIOPRINE; COTRIMOXAZOLE; CYCLOSPORIN A; HEPATITIS C ANTIBODY; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; PREDNISONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CALCULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HEMODIALYSIS; HEPATITIS C; HUMAN; HUMAN CELL; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; MICROEMULSION; PHARMACOLOGICAL PARAMETERS; POLYMERASE CHAIN REACTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; VIREMIA;

ADULT; CYCLOSPORINE; FEMALE; HEPATITIS C ANTIBODIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED;

EID: 8644269824     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2004.00256.x     Document Type: Article

References (27)

1. First MR, Schroeder TJ, Monaco AP, Simpson MA, Curtis JJ, Armenti VT. Cyclosporine bioavailability: dosing implications and impact on clinical outcomes in select transplantation subpopulations. Clin Transplant 1996: 10: 55.
2. Choo Q, Kuo G, Weiner AJ et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B, viral hepatitis genome. Science 1989: 244: 358.
3. Karohl C, Manfro RC, Gonçalves LF et al. Prevalência de anticorpos anti-vírus da hepatite C em pacientes em hemodiá lise crônica de Porto Alegre. J Bras Nefrol 1995: 17: 40.
4. Manfro RC, Karohl C, Gonçalves LF et al. Liver function tests in hepatitis C virus infected kidney transplant recipients. Transplant Proc 1995: 27: 1821.
5. Tuncer M, Süleymanlar G, Ersoy FF, Yakupoglu G. Effects of hepatitis C virus infection on cyclosporine trough levels in renal transplant patients. Transplant Proc 2000: 32: 569.
6. Wolffenbüttel L, Giugliane EAP, Manfro RC, Gonçalves LFS. Elevated cyclosporine A trough levels in HCV positive kidney transplant recipients. Rev Assoc Med Bras 2003: 49: 141.
7. Silva Júnior HT, Pereira AB, Ajzen H et al. Farmacocinética da ciclosporina e de Sens metabólitos em pacientes submetidos a transplante renal. Rev Assoc Med Bras 1994: 40: 159.
8. Kahan BD, Kramer WG, Wideman C et al. Demographic factors affecting the pharmacokinetics of cyclosporine estimated by radioimmunoassay. Transplantation 1986: 41: 459.
9. Ptachcinski RJ, Venkataramanam R, Burckart GJ. Clinical pharmacokinetics of cyclosporine. Clin Pharmacokinet 1986: 11: 107.
10. Yee GC, Lennon TP, Gmar DJ et al. Effect of age on cyclosporine kinetics in marrow transplant recipients. Transplant Proc 1987: 19: 1704.
11. Drewe J, Meier R, Vonderscher J et al. Enhancement of the oral absorption of cyclosporine in men. Br J Clin Pharmacol 1992: 34: 60.
12. Kovarik JM, Mueller EA, Van Bree JB et al. Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J Pharm Sci 1994: 83: 444.
13. Mueller EA, Kovarik JM, Van Bree JB et al. Influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine in a crossover comparison with the market formulation. Pharm Res 1994: 11: 151.
14. Wacke R, Bast R, Rohde B et al. Pharmacokinetic studies of oral and intravenous cyclosporine in prekidney transplant patient. Transplant Proc 1998: 30: 1663.
15. Foradori AC, Martinez L, Elberg A et al. Preliminary pharmacokinetic evaluation of a new galenical formulation of oral cyclosporine A: Neoral™. Transplant Proc 1995: 27: 1813.
16. Keown PA, Niese D. Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. Kidney Int 1998: 54: 938.
17. Kovarik JM, Mueller EA, Van Bree JB et al. Cyclosporine pharmacokinetics and variability from a microemulsion formulation - a multicenter investigation in kidney transplant patients. Transplantation 1994: 58: 658.
18. Sketris IS, Lawen JG, Zollinger-Beauregard L et al. Comparison of the pharmacokinetics of cyclosporine Sandimmune with Sandimmune Neoral in stable renal transplant patient. Transplant Proc 1994: 26: 2961.
19. Kaplan B, Lown K, Craig R. et al. Low bioavailability of cyclosporine microemulsion and tacrolimus in a small bowel transplant recipient: possible relationship to intestinal P-glycoprotein activity. Transplantation 1999: 67: 333.
20. Lown KS, Mayo RR, Leichtman AB et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997: 62: 248.
21. Kammer AR. Molecular mimicry of human cytochrome P450 by hepatitis C virus at the level of cytotoxic T cell recognition. J Exp Med 1999: 190: 169.
22. Lytton SD. Autoantibodies against cytochrome P-4502E1 and P4503A in alcoholics. Mol Pharmacol 1999: 55: 223.
23. Christians U, Bleck JS, Lampen A et al. Are cytochrome P450 3A enzymes in the small intestine responsible for different cyclosporine metabolite patterns is stable male and female renal allograft recipients after co-administration of diltiazem? Transplant Proc 1996: 28: 2159.
24. Mathis AS, Di Renzo T, Friedman GS et al. Sex and ethnicity may chiefly influence the interaction of fluconazole with calcineurin inhibitors. Transplantation 2001: 71: 1069.
25. Hunt CM, Westerkam WR, Stave GM et al. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 1992: 44: 275.
26. Gentil MA, Rocha JL, Rodriguez-Algarra G et al. Impaired kidney transplant survival in patients with antibodies to hepatitis C virus. Nephrol Dial Transplant 1999: 14: 2455.
27. UlfMeier-Kriesche H, Ojo AO, Hanson JA, Kaplan B. Hepatitis C antibody status and outcomes in renal transplant recipients. Transplantation 2001: 72: 241.